Star Health Insurance executed a clear operational turnaround in FY26 — the most important metric being underwriting profit swinging from a ₹165 crore loss in FY25 to a ₹206 crore profit. GWP grew 17% to ₹20,369 crore. Reported PAT of ₹911 crore understates performance: normalised PAT is ₹1,222 crore after adjusting for ₹558 crore MTM equity losses from market volatility. Good sentiment, high confidence.
Headline Numbers
| Metric | FY26 | Notes |
|---|---|---|
| GWP (Full Year) | ₹20,369 crore | +17% YoY |
| GWP (Q4 FY26) | ₹6,259 crore | +17% YoY |
| Underwriting Profit (FY26) | ₹206 crore | Swing from -₹165 cr in FY25 |
| Underwriting Profit (Q4) | ₹186 crore | +200% YoY |
| Reported PAT (FY26) | ₹911 crore | Includes ₹558 cr MTM loss |
| Normalised PAT (FY26) | ₹1,222 crore | Ex-MTM equity loss |
What Drove the Results
- Underwriting discipline is the core achievement: The swing from -₹165 crore underwriting loss (FY25) to +₹206 crore underwriting profit (FY26) was built on three foundations: analytics-led pricing (risk-based instead of market-following), portfolio optimisation (exiting or repricing high-loss segments), and fraud/waste reduction programs. Q4 alone delivered ₹186 crore underwriting profit — a 200% YoY improvement.
- GWP +17% with better quality mix: Revenue grew 17% while underwriting improved — a combination that typically doesn't happen in insurance without portfolio quality improvement. The shift toward the "new-to-insurance" retail segment (first-time buyers, younger profiles) with better loss characteristics drove both growth and margin improvement.
- GST exemption is a structural demand tailwind: The government's GST exemption on retail health insurance reduced effective premiums for buyers, stimulating demand — particularly in the mass market segment that Star Health targets. This is a policy tailwind that benefits Star Health disproportionately given its focus on retail versus group health.
- MTM equity loss of ₹558 crore is noise, not signal: Global equity market volatility from geopolitical tensions (West Asia) caused mark-to-market losses on Star Health's investment portfolio. These are non-cash, accounting-driven, and reverse when markets recover. Normalised PAT of ₹1,222 crore is the relevant operating metric — representing a 34% premium over reported PAT.
- Proprietary channel growth: Management has consistently invested in growing Star Health's proprietary distribution (direct sales, digital channels) rather than relying entirely on agents. This reduces distribution costs over time and improves retention.
What Management Said
Management was composed and specific — entering FY27 with "unchanged priorities." On underwriting: "The improvement is driven by analytics-led pricing, portfolio optimisation, and fraud management — not by price hikes alone." On GST: "Pricing is based on product performance and actuarial principles, not on GST. GST benefits are fully passed on to customers." On loss ratio target: "Retail loss ratio trajectory continues improving toward 65-66% — the path is analytics, not just luck." The high confidence reading reflects management's discipline and specificity across all operational metrics.
Key Tailwinds and Risks
Tailwinds:
- GST exemption on retail health insurance — structural demand catalyst for Star Health's core segment
- India's health insurance penetration is low — universal health coverage target by 2047 is a decade-long growth runway
- Regulatory tailwinds: IND AS adoption, Bima Sugam, Public Insurance Registry improving industry efficiency
- Underwriting discipline now embedded — Q4 +200% YoY underwriting profit shows it's not seasonal
Risks:
- MTM equity losses from equity market volatility (₹558 crore in FY26) — not operational, but impacts reported PAT
- Vector-borne disease seasons (dengue, malaria) cause high-frequency seasonal claim spikes
- Intense competition in health insurance — pricing discipline must be maintained against competitors chasing growth
- Distribution cost: balancing proprietary channel investment vs. agent-led growth
StockMirror AI Signal Summary
| Signal | Reading |
|---|---|
| Overall Sentiment | Good |
| Management Confidence | High |
| Prepared Remarks | Good — confident, disciplined language, specific on underwriting methodology |
| Q&A Sentiment | Good — direct answers on loss ratio path and pricing philosophy |
| Revenue Growth | On track — GWP +17% YoY, demand tailwind from GST exemption |
| Margin Direction | Expanding — underwriting profit turning positive is the key inflection |
| Earnings Quality | Mostly clean — ₹558 crore MTM loss is non-cash; normalised PAT ₹1,222 crore |
See Star Health's complete AI signal breakdown — underwriting profit trajectory, loss ratio trends, and claims analysis — at Star Health's earnings page.
Key Takeaways
- FY26 underwriting profit ₹206 crore — swing from -₹165 crore (FY25), the key turnaround metric
- GWP ₹20,369 crore (+17% YoY); Q4 alone: GWP ₹6,259 crore, underwriting profit +200% YoY
- Reported PAT ₹911 crore; normalised PAT ₹1,222 crore (₹558 crore MTM equity loss excluded)
- GST exemption on retail health insurance is a structural demand catalyst
- Underwriting improvement built on analytics-led pricing + portfolio quality, not just price hikes
- FY27: unchanged priorities — proprietary channel growth, retail segment focus
Frequently Asked Questions
What was Star Health's underwriting profit in FY26? Star Health reported an underwriting profit of ₹206 crore for FY26 — a significant swing from an underwriting loss of ₹165 crore in FY25. Q4 FY26 underwriting profit was ₹186 crore (+200% YoY). This is the most important operating metric for a health insurer, as it measures whether the core insurance business is profitable before investment income.
What is the difference between Star Health's reported PAT and normalized PAT? Reported FY26 PAT is ₹911 crore. Normalised PAT is ₹1,222 crore. The ₹311 crore gap is primarily from a ₹558 crore MTM (mark-to-market) equity investment loss caused by market volatility from geopolitical tensions. MTM movements are non-cash and accounting-driven — they reverse when markets recover. For operating performance, normalised PAT is the correct metric.
What does the GST exemption mean for Star Health? The Indian government granted GST exemption on retail health insurance products, reducing the effective premium cost for buyers. Since Star Health is primarily a retail health insurer, this directly boosts demand for its products. Management passes the full GST benefit to customers and does not use it for price management — the demand stimulus is structural and ongoing.
How does Star Health plan to sustain the underwriting improvement? Management's approach is analytics-driven pricing (pricing each policy segment based on actual loss experience rather than market rates), portfolio optimisation (reducing exposure to high-loss customer segments), and scaled-up fraud and waste reduction. The loss ratio improvement is gradual but consistent — targeting retail loss ratios of 65-66% over time.
Related: Bajaj Housing Finance Q4 FY26 · ICICI Prudential Life Q4 FY26 · Banking Sector Stocks India
Disclaimer: This article is for informational purposes only and does not constitute investment advice. StockMirror's AI analysis is based on publicly available earnings transcripts and BSE/NSE filings. Please consult a SEBI-registered financial advisor before making investment decisions.